This cohort study investigates the association of changes in levels of plasma tau phosphorylated at threonine 181 and neurofilament light chain protein with psychotic symptoms in Alzheimer disease.
Risultati per: La carne alla griglia favorisce Alzheimer e diabete
Questo è quello che abbiamo trovato per te
Alzheimer, la «vecchia» liraglutide aiuta a proteggere il cervello
Un nuovo studio suggerisce che il primo farmaco Glp-1 impiegato per combattere diabete e obesità, può ridurre la perdita di massa cerebrale
Un nuovo test del sangue per diagnosticare l'Alzheimer al 90%
Lo conferma uno studio su 1.200 persone
SIGN: Gestione del diabete in gravidanza.
What a Neurologist With Alzheimer Disease Wants People to Know
This Medical News article is an interview with retired neurologist Daniel Gibbs, who is living with Alzheimer disease.
Efficacia e sicurezza dei farmaci GLP-1 per il diabete di tipo 2 e l’obesità
Nuovi criteri diagnostici per la malattia di Alzheimer
Diabete tipo 2: il digiuno intermittente supera i farmaci tradizionali
Study: 2 APOE4 Copies May Indicate Genetic Form of Alzheimer Disease
Almost all people who inherited 2 identical copies of the APOE4 gene variant had abnormally high levels of amyloid in their cerebrospinal fluid and brain by age 65 years, according to a new study that combined data from more than 3200 brain donors and about 10 000 participants with clinical data.
Alzheimer’s Disease, Biomarkers, and mAbs — What Does Primary Care Need?
New England Journal of Medicine, Ahead of Print.
Protection against Alzheimer’s Disease with APOE Christchurch Variant — How?
New England Journal of Medicine, Volume 390, Issue 23, Page 2212-2213, June 20, 2024.
Homozygosity for R47H in TREM2 and the Risk of Alzheimer’s Disease
New England Journal of Medicine, Volume 390, Issue 23, Page 2217-2219, June 20, 2024.
APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease
New England Journal of Medicine, Volume 390, Issue 23, Page 2156-2164, June 20, 2024.
Risks of Harm in Alzheimer Disease by Amyloid Lowering
This Viewpoint discusses how data gaps in published research impede clinicians’ ability to clearly discuss the risks and benefits of amyloid-lowering drugs for treating Alzheimer disease.
Il controllo del mercato dei farmaci per l’Alzheimer
I consulenti dell’Fda hanno approvato il farmaco di Eli Lilly. Entro la fine dell’anno si attende l’ok definitivo da parte dell’Ente regolatorio
Oltre 200 farmaci contro il diabete dall’ospedale alla farmacia sotto casa
Si tratta di medicinali spesso essenziali finora reperibili solo nelle farmacie degli ospedali